Host: The 92nd Annual Meeting of the Japanese Pharmacological Society
Name : The 92nd Annual Meeting of the Japanese Pharmacological Society
Number : 92
Location : Osaka
Date : March 14, 2019 - March 16, 2019
The onset and progression of Alzheimer's disease (AD) correlate with neuroinflammatory processes, and inflammatory microglia (MG) are associated with AD-like pathology in a transgenic mouse model. However, the distinct role of MG subtypes in AD brain remains unclear. We recently developed a novel monoclonal antibody, 9F5, against one subtype (type 1) of rat primary MG, and identified the antigen molecule for 9F5: truncated form of rat GPNMB/osteoactivin (Kawahara et al., GLIA, 2016). In neonatal rat brain, GPNMB+Iba1+ MG were a portion of Iba1+ MG, and were observed in specific brain areas including corpus callosum. However, the distribution and function of GPNMB+ type 1 MG in AD brain are largely unknown. In the present study, we observed GPNMB+Iba1+ MG surrounding Aβ plaque in neocortex of amyloid precursor protein (APP23) transgenic mice. In addition, GPNMB+Iba1+ MG were observed in non-plaque areas of hippocampus of APP23 mice. We generated Gpnmb knockout mice to investigate the functional relevance of GPNMB for microglia in vivo. Homozygous Gpnmb-KO mice did not show any growth retardation including body weight loss, and the fertility was normal. We observed that AD-related brain dysfunction in APP23 mice were regulated by Gpnmb gene dosage. These finding suggest that GPNMB+ type 1 MG may play a role in regulation of neuropathological process of AD.
